191 related articles for article (PubMed ID: 29789639)
1. Fludarabine and neurotoxicity in engineered T-cell therapy.
Lowe KL; Mackall CL; Norry E; Amado R; Jakobsen BK; Binder G
Gene Ther; 2018 Jun; 25(3):176-191. PubMed ID: 29789639
[TBL] [Abstract][Full Text] [Related]
2. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
Kochenderfer JN; Somerville RPT; Lu T; Shi V; Bot A; Rossi J; Xue A; Goff SL; Yang JC; Sherry RM; Klebanoff CA; Kammula US; Sherman M; Perez A; Yuan CM; Feldman T; Friedberg JW; Roschewski MJ; Feldman SA; McIntyre L; Toomey MA; Rosenberg SA
J Clin Oncol; 2017 Jun; 35(16):1803-1813. PubMed ID: 28291388
[TBL] [Abstract][Full Text] [Related]
3. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
4. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
Nissani A; Lev-Ari S; Meirson T; Jacoby E; Asher N; Ben-Betzalel G; Itzhaki O; Shapira-Frommer R; Schachter J; Markel G; Besser MJ
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33990415
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Dekker L; Calkoen FG; Jiang Y; Blok H; Veldkamp SR; De Koning C; Spoon M; Admiraal R; Hoogerbrugge P; Vormoor B; Vormoor HJ; Visscher H; Bierings M; Van Der Vlugt M; Van Tinteren H; Nijstad AL; Huitema ADR; Van Der Elst KCM; Pieters R; Lindemans CA; Nierkens S
Blood Adv; 2022 Apr; 6(7):1969-1976. PubMed ID: 35134115
[TBL] [Abstract][Full Text] [Related]
7. Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy.
Zhang WY; Liu Y; Wang Y; Nie J; Guo YL; Wang CM; Dai HR; Yang QM; Wu ZQ; Han WD
Gene Ther; 2018 Jun; 25(3):198-204. PubMed ID: 29599530
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of cyclophosphamide and fludarabine combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies
Xia Z; Tian M; Cheng Y; Yi W; DU Z; Li T; Wen Y; Li L; Liu Y; Chen C
Oncol Res; 2024; 32(6):1109-1118. PubMed ID: 38827326
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
[TBL] [Abstract][Full Text] [Related]
10. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.
Turtle CJ; Riddell SR; Maloney DG
Clin Pharmacol Ther; 2016 Sep; 100(3):252-8. PubMed ID: 27170467
[TBL] [Abstract][Full Text] [Related]
11. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Gauthier J
Bull Cancer; 2018 Dec; 105 Suppl 2():S214-S217. PubMed ID: 30686360
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
Wallen H; Thompson JA; Reilly JZ; Rodmyre RM; Cao J; Yee C
PLoS One; 2009; 4(3):e4749. PubMed ID: 19270751
[TBL] [Abstract][Full Text] [Related]
15. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
16. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
17. Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting.
Green S; Schultz L
Curr Oncol Rep; 2023 Aug; 25(8):841-846. PubMed ID: 37099243
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell therapies for lymphoma.
Brudno JN; Kochenderfer JN
Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
[TBL] [Abstract][Full Text] [Related]
19. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.
Gust J; Taraseviciute A; Turtle CJ
CNS Drugs; 2018 Dec; 32(12):1091-1101. PubMed ID: 30387077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
